SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE is trending as the community rallies around the return of "OG Memes" and 2021 vibes, fueled by bullish sentiment following recent market events. Community members are actively promoting its strong community and potential for significant growth, emphasizing the importance of conviction. Discussions also revolve around potential exchange listings and the revival of Rage Comics.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The "crow with knife" meme coin, $CAW, is gaining traction as community members rally around its self-described "organic" and "deflationary" nature.   bridging and burning tokens, as well as potential staking opportunities. Bullish sentiment is high among holders, with many declaring it the "only option."

ARB IOT Group Ltd. is a holding company that engages in the provision of solutions for the integration of IoT systems and devices. It operates through the Internet of Things and Investment Holding and Others segments. The company was founded on March 1, 2022 and is headquartered in Singapore.

ARB IOT Group Ltd

ARBB is trending due to renewed discussions around a past AI server deal and its low float, leading to speculation of a potential short squeeze. Community members are actively watching key breakout levels, anticipating a move to higher price targets. The stock's previous run and current setup are fueling interest among traders looking for the next low-float runner.

Bondex is a web 3.0 professional network where users own part of the ecosystem earn rewards and monetise their network.

Bondex

Bondex ($BDXN) is trending as traders discuss its potential in the Web3 talent network, especially after a recent token unlock event that it weathered smoothly, signaling strong demand. The community is also excited about its growing trading volume and recent listing on Bybit Futures perpetual, with some drawing comparisons to early-stage Solana. Some users speculate that the Remote3 acquisition strengthens the project.

The Aircoin memecoin was born from a viral Twitter post from March, 2014 which proclaimed the following:   Evolution: 1. Aircoin 2. Fartcoin 3. Artcoin  Aircoin was launched in August, 2025 and CTO'd twice, with the second CTO team bringing vast experience and expertise to the project. The team includes industry veterans and visual arts professionals.  Aircoin is destined for greatness as a premier memecoin on the BONK.fun platform.

aircoin

Aircoin is trending as the community eagerly anticipates the launch of "AirLock," a feature designed to reward token holders and promote a strong hodling culture. Discussions highlight the potential for community-owned supply control and the team's commitment to exchange listings, driving excitement around the project's future within the Solana ecosystem.

Aurora Cannabis, Inc. engages in the production, distribution, and sale of cannabis and cannabis-derivative products. It operates through the Cannabis and Plant Propagation segments. The company was founded by Terry Booth and Steve Dobler on December 21, 2006 and is headquartered in Edmonton, Canada.

Aurora Cannabis Inc

Aurora Cannabis is trending as cannabis stocks react to reports that the Trump administration is considering loosening federal restrictions on marijuana, potentially reclassifying it as a Schedule III drug; this has ignited speculation about the impact on the sector. Community discussions focus on the potential benefits of reclassification, including access to banking services and reduced tax burdens, while some caution against overhyping the news until an official order is signed.

Berachain

Berachain ($BERA) is trending as the community discusses its Proof-of-Liquidity model and recent integrations, including PAW Chain and Bancor's Arb Fast Lane. Community members are debating its potential, TVL, and recent price action, while also watching for potential breakout points and exchange listings. Some users express concerns about token distribution, while others highlight positive aspects such as governance upgrades and real-world utility.

Codatta

XNY (Codatta) is gaining traction as traders discuss its potential for another significant surge, reminiscent of a prior 300% increase. Community members are closely watching its chart patterns, noting bullish formations and strong support levels, particularly in relation to Bitcoin's movements. Interest is also building around Codatta's role in AI data and its fingerprint verification technology.

Amplify ETF Trust - Amplify Seymour Cannabis ETF

Amplify Seymour Cannabis ETF

$CNBS is trending as cannabis stocks experience volatility amid discussions of potential federal regulatory changes, including reclassification, with some in the community pointing to executive action. The community is focused on the potential impacts of any changes, especially tax relief and banking access, while also scrutinizing sector leaders and potential market manipulation. Recent market activity and unusual options activity are also being closely monitored by investors.

FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.

FibroGen Inc

Recent insider buying, particularly by the CEO, and analyst reiteration of a Buy rating with a $10 price target are driving interest in FibroGen. Community members are actively discussing the upcoming reverse stock split and its potential impact, with some expressing concerns while others hope it will attract institutional investment. Anticipation surrounds the closing of the China sale to AstraZeneca, which is expected to improve FibroGen's cash position and extend its runway into 2027, allowing focus on oncology trials.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Ligand Pharmaceuticals and Pelthos Therapeutics rose on Thursday after the commercial launch of Zelsuvmi (berdazimer) topical gel, developed under their partnership,&nbsp;to treat a common viral skin infection.<a href="https://stocktwits.com/symbol/PTHS">Pelthos Therapeutics</a> surged 60.8% to close at $10.01 on Thursday, while&nbsp;<a href="https://stocktwits.com/symbol/LGND">Ligand Pharmaceuticals</a> gained 2.1%.The launch triggered a $5 million milestone payment to Ligand under the companies’ license agreement. Under the terms of the licensing deal, Ligand is also entitled to a 13% royalty on worldwide sales of Zelsuvmi and up to $5 million in additional commercial milestones.Ligand also holds a 56% equity stake in Pelthos following the completion of a merger between Pelthos and Channel Therapeutics on July 2.Pelthos announced the merger earlier this month, in which CHRO Merger Sub, a wholly owned subsidiary of Channel, merged with LNHC, a wholly owned subsidiary of Ligand.&nbsp;LNHC survived as a subsidiary of Channel, and the combined company is now operating under the Pelthos Therapeutics name. Concurrent with the merger, Pelthos raised $50.1 million in a private placement led by Murchinson.&nbsp;The investment included new equity as well as the cancellation of $18.8 million in previously advanced bridge capital used to support the commercial launch of Zelsuvmi.Zelsuvmi is a nitric oxide-releasing topical gel approved by the U.S. Food and Drug Administration in 2024 for the treatment of molluscum contagiosum,&nbsp;sometimes known commonly as “water warts”, in patients aged one year and older.&nbsp;It is the first prescription medication approved for at-home application by patients, parents, or caregivers. The product was developed using the nitric oxide-based Nitricil platform, now owned by Ligand.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.On Stocktwits, retail sentiment for both Ligand Pharmaceuticals and Pelthos Therapeutics was ‘bullish’, with ‘high’ message volume for Ligand and ‘extremely high’ activity for Pelthos.Ligand’s stock has gained 15.3%so far in 2025, while Pelthos has surged 266.3% over the same period.See also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-threatens-canada-with-35-tariff-by-august-mulls-blanket-rates-for-others/ch8TD9uR5l4">Trump Threatens Canada With 35% Tariff By August, Mulls Blanket 15-20% Rates For Other Countries</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ligand Pharmaceuticals (LGND) and Pelthos Therapeutics (PTHS) commercially launched Zelsuvmi (berdazimer) topical gel (Photo credit: Getty Images)

Pelthos, Ligand Gain After Launch Of First Prescription-At-Home Treatment For Water Warts

The launch triggered a $5 million milestone payment to Ligand, which also holds a 56% stake in Pelthos and is eligible for royalties and additional commercial milestones.

Equity

Pelthos Therapeutics, Inc. engages in the provision of therapeutic products. It produces products under its proprietary nitic oxide-based technology platform Nitricil. Its main product is a topical gel for the treatment of molluscum contagiosum. The company was founded on March 19, 2021 and is headquartered in Durham, NC.

PTHS
Pelthos Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PTHS News

PTHSPelthos Therapeutics Inc.